Obsessive-Compulsive Disorder: June 2015
Keck School of Medicine of USC and Psychiatric Annals
Table of Contents
Obsessive-Compulsive Disorder: Overview and Standard Treatment Strategies
Phillip J. Seibell, MD; Rebecca J. Hamblin, PhD; and Eric Hollander, MD
Cognitive-Behavior Therapy Outcomes for Obsessive-Compulsive Disorder: Exposure and Response Prevention
Michael G. Wheaton, PhD; Marissa R. Schwartz, BA; Olivia Pascucci, BA; and H. Blair Simpson, MD, PhD
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Christopher Pittenger, MD, PhD
Outcomes with Neuromodulation in Obsessive-Compulsive Disorder
Stefano Pallanti, MD, PhD; Anna Marras, MSc; and Giacomo Grassi, MD
Sponsorship Statement: This CME activity is jointly sponsored by Keck School of Medicine of USC and Psychiatric Annals.
Support Statement: There is no commercial support for this activity.
1. Assess obsessive-compulsive disorder and describe typical symptomatology.
2. Describe exposure and response prevention treatment for obsessive-compulsive disorder.
3. Describe the evidence-based off-label use of glutamate modulators in the treatment of refractory obsessive-compulsive disorder.
4. Discuss neurocircuitry-targeted approaches to treating treatment-resistant obsessive-compulsive disorder.
Faculty names and affiliations: See authors above
Guest Editor: Phillip J. Seibell, MD
Reviewer names: Jan Fawcett, MD, Editor, Psychiatric Annals; Andrew A. Nierenberg, MD, CME Coordinator, Psychiatric Annals
Disclosure statement: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue and also on this page.
Faculty members report the following financial relationships:
Jan Fawcett, MD, has no relevant financial relationships to disclose.
Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly and Company; EpiQ, Forest; Johnson and Johnson; Labopharm; Merck; Methylation Science; Novartis; PamLabs; PGx Health; Shire; Schering-Plough; Sunovion; Takeda/Lundbeck Pharmaceuticals; Targacept; Teva: Consultant. APSARD; Belvoir Publishing; Boston Center for the Arts; University of Texas Southwestern Dallas; Hillside Hospital; American Drug Utilization Review; American Society for Clinical Psychopharmacology; Bayamon Region Psychiatric Society; Baystate Medical Center; Canadian Psychiatric Association; Columbia University; Douglas Hospital/McGill University; IMEDEX; International Society for Bipolar Disorders; Israel Society for Biological Psychiatry; John Hopkins University; MJ Consulting; Massachusetts Association of College Counselors; Medscape; MBL Publishing; Physicians Postgraduate Press; Ryan Licht Sang Foundation; Slack Publishing; SUNY Buffalo; University of Florida; University of Miami; University of Wisconsin; University of Pisa; SciMed: Honoraria / travel expenses. Appliance Computing, Inc.; Brain Cells, Inc.: Stock options. AHRQ; Cephalon; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals; Takeda; Elan; Shire: Grant / research support.
Authors report the following financial relationships: Phillip J. Seibell discloses fees received for non-CME services from Sunovion Pharmaceuticals-Speakers Bureau and honoraria received from the British Medical Group and the Nevada Psychiatric Association. Rebecca J. Hamblin has no relevant financial relationships to disclose. Eric Hollander discloses contracted research for Brainsway. Michael G. Wheaton has no relevant financial relationships to disclose. Marissa R. Schwartz has no relevant financial relationships to disclose. Olivia Pascucci has no relevant financial relationships to disclose. H. Blair Simpson discloses royalties received from UpToDate, Inc and Cambridge University Press. Christopher Pittenger has performed contracted research for F. Hoffmann-La Roche Ltd. Stefano Pallanti has no relevant financial relationships to disclose. Anna Marras has no relevant financial relationships to disclose. Giacomo Grassi has no relevant financial relationships to disclose.
The staff of Keck School of Medicine of USC and Psychiatric Annals have disclosed no relevant financial relationships.
Signed disclosures are on file at Keck School of Medicine of USC.
Accreditation statement(s): This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Keck School of Medicine of USC and SLACK Incorporated. The Keck School of Medicine of USC is accredited by the ACCME to provide continuing medical education for physicians.
Credit designation: The Keck School of Medicine of USC designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: June 1, 2015.
Expiration Date: June 30, 2018.
How to participate: To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Keck School of Medicine of USC will issue an AMA PRA Category 1 Credit(s)™ certificate.
Target audience: This CME activity is primarily targeted to patient-caring psychiatrists, physicians specializing in psychiatry and others allied to the field. There are no specific background requirements for participants taking this activity. Learning objectives and author disclosures are found at the beginning of each CME article.
Unlabeled and investigational usage statement: The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Copyright statement: Copyright © 2015 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.